Evident Vascular
Series B in 2025
Evident Vascular specializes in advanced intravascular ultrasound (IVUS) technology, enhanced by artificial intelligence. Their platform automatically identifies and segments key vascular structures in real-time, aiding clinicians in decision-making and improving patient care during peripheral vascular image-guided therapies.
Alleviant Medical
Venture Round in 2025
Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.
Okami Medical
Venture Round in 2024
Okami Medical, Inc. is a medical device manufacturer based in Aliso Viejo, California, specializing in the occlusion of peripheral vessels to treat cardiovascular disease. The company's flagship product, the LOw-profile Braided Occluder (LOBO), is designed to provide interventional physicians with a single, versatile device for occluding various arterial targets without the need for multiple embolic devices. The LOBO system features a patented design and proprietary HDBRAID technology, which creates a highly occlusive pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011, Okami Medical aims to meet the evolving needs of patients and healthcare providers by offering innovative solutions that ensure rapid and reliable vessel occlusion, regardless of anatomical challenges.
iVEAcare specializes in developing advanced neuromodulation therapies to address unmet clinical needs, focusing on chronic diseases. The company creates innovative devices and software that deliver targeted electrical stimulation to specific areas of the brain or spinal cord, aiming to enhance treatment effectiveness and reduce invasiveness.
Elucent Medical
Series C in 2024
Elucent Medical LLC is a healthcare company focused on enhancing breast cancer treatment. Established in 2014 and headquartered in Brookfield, Wisconsin, Elucent Medical creates and commercializes a wireless marker tag and detection system that improves the localization of breast abnormalities during surgical excision. Their advanced surgical navigation technology relies on real-time data processing to accurately identify surgical markers, which helps in determining tumor margins and ultimately contributes to better patient outcomes. By streamlining the surgical process and eliminating the need for traditional metal clips, Elucent Medical aims to make breast cancer procedures more accessible and affordable while enabling surgeons to effectively preserve breast tissue during cancer removal. The company's innovations serve both healthcare providers and patients, enhancing the overall efficacy of breast cancer surgeries.
Evident Vascular
Series A in 2023
Evident Vascular specializes in advanced intravascular ultrasound (IVUS) technology, enhanced by artificial intelligence. Their platform automatically identifies and segments key vascular structures in real-time, aiding clinicians in decision-making and improving patient care during peripheral vascular image-guided therapies.
Spyglass Pharma
Series C in 2023
Spyglass Pharma specializes in developing innovative treatments for chronic eye diseases using advanced technologies. The company aims to deliver multiple drugs to address additional ophthalmic indications.
Artelon is a company focused on advancing orthopedic soft tissue reconstruction through innovative tissue-regrowth technology. It specializes in the development of synthetic materials specifically designed for tendon and ligament reconstruction, aiming to enhance stability and motion in affected joints. By creating bio-textiles that provide kinematic reinforcement, Artelon enables surgeons to effectively restore joint strength and functionality. The company is dedicated to improving patient outcomes in joint instability cases through its novel reconstructive products and procedures, as well as offering consulting support to aid in patient recovery.
Relievant Medsystems
Venture Round in 2023
Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.
Alleviant Medical
Venture Round in 2023
Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.
Volta Medical
Series B in 2023
Founded in 2016 and based in Marseille, France, Volta Medical develops artificial intelligence software for interventional cardiology. Its flagship product, AIFib, assists cardiologists in treating atrial fibrillation by analyzing electrograms and guiding cardiac ablation procedures.
Nyra Medical
Series A in 2022
Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.
Cleerly is a healthcare company developing digital care pathways to prevent heart attacks by establishing a new standard of care for coronary artery disease. The company combines clinical science with next-generation AI to deliver actionable insights across the heart care pathway, including a non-invasive platform that quantifies and characterizes plaque buildup in heart arteries. Its solutions aim to help healthcare providers identify at-risk patients early and support cost-effective prevention, ultimately improving cardiovascular outcomes and delivering value to the health system.
Moxe Health specializes in facilitating the exchange of clinical data between health plans and provider systems. Its platform, Substrate, enables real-time, bi-directional data transfer, including clinical, analytic, and administrative information. Moxe's solutions cover risk adjustment, quality metrics (like HEDIS and Star ratings), claims management, and care gap management, ensuring health plans and providers have the necessary data for value-based care. The company's neutrality allows seamless integration with existing systems, maximizing investments in population health and analytics.
Apella is a medical technology company that uses artificial intelligence, computer vision, and sensor data from operating rooms to digitize surgical workflows. Its platform collects real-time data from in-room devices to analyze surgical procedures and provide actionable insights for process improvement, quality control, training, and real-time decision support, with the goal of improving surgical outcomes. The company was founded in 2019 and is headquartered in San Francisco.
Cleerly is a healthcare company developing digital care pathways to prevent heart attacks by establishing a new standard of care for coronary artery disease. The company combines clinical science with next-generation AI to deliver actionable insights across the heart care pathway, including a non-invasive platform that quantifies and characterizes plaque buildup in heart arteries. Its solutions aim to help healthcare providers identify at-risk patients early and support cost-effective prevention, ultimately improving cardiovascular outcomes and delivering value to the health system.
GPB Scientific
Venture Round in 2021
GPB Scientific, LLC is a biotechnology company specializing in the development of a liquid biopsy platform designed to isolate rare circulating tumor cells from a patient's blood while preserving their viability. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating red blood cells and normal white blood cells to yield a population of rare tumor cells. Founded in 2002 and based in Richmond, Virginia, GPB Scientific markets its innovative technology to life sciences companies and research institutions, boasting a robust portfolio of patents and expertise in microchip technology for size-based enrichment and affinity-based cell capture.
Personal Genome Diagnostics
Series C in 2021
Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.
Spyglass Ophthalmics
Series B in 2021
Spyglass Ophthalmics, Inc. is a company based in Mission Viejo, California, specializing in the development of ophthalmic therapeutic devices. Founded in 2019, Spyglass focuses on creating innovative solutions to enhance vision and eye care for patients. The company's products target unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic diseases. By providing these devices, Spyglass aims to ensure that patients receive quality eye treatment at an affordable cost.
Relievant Medsystems
Venture Round in 2020
Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.
CVRx
Venture Round in 2020
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.
GPB Scientific
Venture Round in 2020
GPB Scientific, LLC is a biotechnology company specializing in the development of a liquid biopsy platform designed to isolate rare circulating tumor cells from a patient's blood while preserving their viability. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating red blood cells and normal white blood cells to yield a population of rare tumor cells. Founded in 2002 and based in Richmond, Virginia, GPB Scientific markets its innovative technology to life sciences companies and research institutions, boasting a robust portfolio of patents and expertise in microchip technology for size-based enrichment and affinity-based cell capture.
Intact Vascular
Series D in 2019
Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.
Vesper Medical
Venture Round in 2019
Vesper Medical, Inc. is a medical device company based in Wayne, Pennsylvania, founded in 2016. The company specializes in the development of minimally invasive peripheral vascular products aimed at treating patients with deep venous disease. Its primary offering is the Vesper DUO Venous Stent System, designed specifically for venous stenting. This system features a unique combination of strength and flexibility to address the complex anatomical challenges encountered in the iliac and femoral veins. Vesper Medical is dedicated to creating safe, effective, and user-friendly products that enhance patient care and support healthcare providers in improving patient outcomes in venous treatment.